VBIV · Vbi Vaccines Inc/Bc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21M | - | $6.62M | $720.0K | $485.0K | - | $317.0K | $346.0K | $126.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.57M | - | $1.53M | $3.29M | $3.15M | - | $4.98M | $5.64M | $2.36M | - |
| SG&A | $7.67M | - | $14.22M | $15.08M | $10.93M | - | $14.22M | $15.08M | $10.93M | - |
| Total Operating Expenses | $12.97M | - | $16.69M | $37.69M | $19.99M | - | $21.88M | $23.25M | $16.05M | - |
| D&A | $493.0K | - | - | - | $508.0K | - | - | - | $473.0K | - |
| Operating Income | ($11.75M) | - | ($10.07M) | ($36.97M) | ($19.51M) | - | ($21.56M) | ($22.90M) | ($15.92M) | - |
| Interest Expense | $1.82M | - | $1.54M | $1.71M | $1.43M | - | $958.0K | $901.0K | $940.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($17.90M) | - | ($20.44M) | ($44.63M) | ($27.75M) | - | ($25.21M) | ($45.70M) | ($21.25M) | - |
| EPS - Basic | ($0.73) | - | ($1.01) | ($5.18) | ($3.22) | - | ($0.10) | ($0.18) | ($0.08) | - |
| EPS - Diluted | ($0.73) | - | ($2.93) | ($5.18) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.60M | $23.68M | $35.45M | $20.84M | $40.39M | $62.63M | $83.55M | $82.41M | $101.34M | $121.69M |
| Accounts Receivable | $227.0K | - | $353.0K | $79.0K | $281.0K | $94.0K | $132.0K | $135.0K | $102.0K | $8.0K |
| Inventory | $9.94M | $8.50M | $7.54M | $6.86M | $6.77M | $6.60M | $5.80M | $4.05M | $4.06M | $2.58M |
| Accounts Payable | $8.87M | $6.43M | $7.01M | $7.35M | $9.84M | $12.97M | $11.67M | $5.62M | $3.93M | $4.28M |
| Current Assets | $26.36M | $36.23M | $50.15M | $31.89M | $51.84M | $77.69M | $96.22M | $92.75M | $112.35M | $130.28M |
| Total Assets | $75.44M | $86.95M | $100.78M | $88.32M | $128.46M | $155.09M | $172.01M | $172.16M | $194.01M | $210.28M |
| Current Liabilities | $77.59M | $75.74M | $77.19M | $27.67M | $29.57M | $36.94M | $34.68M | $40.53M | $33.99M | $32.59M |
| Long-term Debt | $48.74M | $50.77M | $50.30M | $47.84M | $49.36M | $48.89M | $48.42M | $21.16M | $24.79M | $28.44M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($5.47M) | $7.53M | $19.89M | $8.74M | $45.02M | $64.16M | $83.82M | $105.56M | $129.56M | $143.88M |
| Retained Earnings | ($600.35M) | ($582.45M) | ($582.43M) | ($561.99M) | ($517.36M) | ($489.61M) | ($468.47M) | ($443.26M) | ($397.56M) | ($378.37M) |
Cash Flow
| Line item | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.77M) | - | - | - | ($21.66M) | - | - | - | ($19.93M) | - |
| Investing Cash Flow | ($151.0K) | - | - | - | ($534.0K) | - | - | - | ($515.0K) | - |
| Financing Cash Flow | $843.0K | - | - | - | - | - | - | - | $12.0K | - |
| CapEx | $151.0K | - | - | - | $534.0K | - | - | - | $515.0K | - |
| Free Cash Flow | ($11.92M) | - | - | - | ($22.19M) | - | - | - | ($20.44M) | - |
Ratios
| Metric | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -968.0% | - | -152.0% | -5135.0% | -4022.5% | - | -6800.6% | -6619.4% | -12634.9% | - |
| EBITDA margin | -927.4% | - | - | - | -3917.7% | - | - | - | -12259.5% | - |
| Net margin | -1474.5% | - | -308.6% | -6198.3% | -5721.9% | - | -7952.4% | -13207.8% | -16868.3% | - |
| Free cash flow margin | -982.0% | - | - | - | -4575.3% | - | - | - | -16222.2% | - |
| FCF / Net income | 0.67 | - | - | - | 0.80 | - | - | - | 0.96 | - |
| R&D / Revenue | 211.8% | - | 23.1% | 457.2% | 649.7% | - | 1571.9% | 1630.9% | 1874.6% | - |
| SG&A / Revenue | 631.9% | - | 214.7% | 2095.0% | 2253.6% | - | 4485.8% | 4359.5% | 8674.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -23.7% | - | -20.3% | -50.5% | -21.6% | - | -14.7% | -26.5% | -11.0% | - |
| Return on equity | 327.4% | - | -102.8% | -510.7% | -61.6% | - | -30.1% | -43.3% | -16.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.34 | 0.48 | 0.65 | 1.15 | 1.75 | 2.10 | 2.77 | 2.29 | 3.31 | 4.00 |
| Quick ratio | 0.21 | 0.37 | 0.55 | 0.90 | 1.52 | 1.92 | 2.61 | 2.19 | 3.19 | 3.92 |
| Cash ratio | 0.16 | 0.31 | 0.46 | 0.75 | 1.37 | 1.70 | 2.41 | 2.03 | 2.98 | 3.73 |
| Leverage | ||||||||||
| Debt / Equity | -8.92 | 6.74 | 2.53 | 5.47 | 1.10 | 0.76 | 0.58 | 0.20 | 0.19 | 0.20 |
| Debt / Assets | 0.65 | 0.58 | 0.50 | 0.54 | 0.38 | 0.32 | 0.28 | 0.12 | 0.13 | 0.14 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -6.5x | - | -6.5x | -21.6x | -13.7x | - | -22.5x | -25.4x | -16.9x | - |
| Equity multiplier | -13.80 | 11.55 | 5.07 | 10.11 | 2.85 | 2.42 | 2.05 | 1.63 | 1.50 | 1.46 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.07 | 0.01 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 68d | - | 19d | 40d | 211d | - | 152d | 142d | 295d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 150.3% | - | 1989.6% | 108.1% | 284.9% | - | 196.3% | 143.7% | -58.1% | - |
| Revenue CAGR (3y) | 59.2% | - | 181.2% | 57.6% | 5.3% | - | -21.2% | 13.9% | -10.9% | - |
| Revenue CAGR (5y) | 46.8% | - | 91.2% | 25.2% | 22.2% | - | 2.4% | 0.1% | 21.3% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 39.8% | - | 53.3% | -61.4% | -22.5% | - | -43.5% | -39.3% | -1.4% | - |
| Net income growth (YoY) | 35.5% | - | 18.9% | 2.3% | -30.6% | - | -59.1% | -161.5% | -20.4% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 46.3% | - | - | - | -8.6% | - | - | - | -183.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -88.3% | -76.3% | -91.7% | -65.3% | -55.4% | -47.7% | -37.2% | -28.0% | -16.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$8.68M totalLicense$3.60M · 41.4%
Product$3.11M · 35.8%
Service$1.98M · 22.8%
Geographic
$8.68M totalChina Hong Kong$5.58M · 64.3%
US$1.84M · 21.3%
Europe$1.08M · 12.5%
IL$167.0K · 1.9%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing VBI Vaccines Inc/BC against the 5 most active filers in the same SIC group.